Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Nutranomics, Inc.
DRAPER, Utah, Oct. 18, 2013 /PRNewswire/ -- Nutranomics, Inc. (OTCBB: NNRX) (OTCQB: NNRX) ("Nutranomics" or the "Company") is pleased to report the summary results of several human patient clinical studies regarding Glucozyme™, a proprietary nutritional supplement developed by Nutranomics to assist in the reduction of blood glucose levels in patients with Type 2 diabetes, which, according to the International Diabetes Federation (IDF), affects more than 371 million people worldwide.
The three separate clinical studies, one conducted "in-house" by Nutranomics, one conducted in a Hispanic clinic in Salt Lake City, Utah, and one conducted by a clinic in Tokyo, Japan, measured both the fasting glucose levels and the HbA1-c levels of Type 2 diabetics for 30, 60, and 90 days. The results of each study showed that Glucozyme™ reduced blood sugar levels and HbA1-c levels in patients by 22-28% within the 90-day period.
"The results of the three separate studies were overwhelmingly positive and show that Glucozyme™ is effective at reducing the blood sugar levels in patients across a diverse ethnic population," said Dr. Tracy K. Gibbs, CEO of Nutranomics. "Based on these results, we are now preparing to launch Glucozyme™ globally."
"Over the next few weeks, we will be making Glucozyme™ directly available on our website and have begun to educate our sales force and distributors about this incredible product designed for the over 371 million people suffering from Type 2 diabetes and the millions more that are at risk of becoming diabetic if they don't get their blood sugar levels in check."
For additional information regarding type 2 diabetes and pre-diabetes (IGT) visit http://www.idf.org/worlddiabetesday/toolkit/gp/facts-figures
Nutranomics is a publicly traded company engaged in research and development of nutritional food products. In 1997, Nutranomics produced and branded its own product line, and began to sell to the retail outlets and to the public. Nutranomics has also produced formulas for hundreds of other companies. Nutranomics' mission is to increase human health and longevity through education and self-awareness. The Company has sales representatives throughout North America and Asia.
For further information regarding Nutranomics, Inc., please contact our investor relations representatives at firstname.lastname@example.org or call toll-free (888) 616-3999.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements." Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include Glucozyme's ability to manage patient glucose levels in all cases, and Glucozyme's potential approval for sale in any jurisdiction. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products and operating as a development stage company, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law, including the securities laws of the United States. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
©2012 PR Newswire. All Rights Reserved.
All content © Copyright 2000 - 2013 WorldNow and KIII. All Rights Reserved.